This inventor holds 8 USPTO granted patents and 5 published patent applications, plus 1 CIPO patent and 3 EPO patents. Top assignee: Incyte Corporation. Active years: 2016-2025.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Location History:
- Wilmington, DE (US) (2016 - 2020)
- Newark, DE (US) (2023)
Company Filing History:
Years Active: 2016-2025
Title: Leah C. Konkol: Innovator in JAK2 V617F Inhibitors
Introduction
Leah C. Konkol is a prominent inventor based in Wilmington, DE (US). She has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that target specific genetic variants associated with various diseases.
Latest Patents
Leah holds a total of 7 patents, with her latest innovations focusing on tricyclic urea compounds as JAK2 V617F inhibitors. These compounds are designed to modulate the activity of the V617F variant of JAK2, which is crucial in the treatment of diseases, including cancer. The applications of her work have the potential to impact therapeutic strategies significantly.
Career Highlights
Leah is currently associated with Incyte Corporation, where she continues to advance her research and development efforts. Her work has been instrumental in pushing the boundaries of what is possible in targeted therapies.
Collaborations
Leah collaborates with talented professionals in her field, including Liangxing Wu and Wenqing Yao. These partnerships enhance the innovative capacity of her projects and contribute to the overall success of her research endeavors.
Conclusion
Leah C. Konkol is a trailblazer in the pharmaceutical industry, with her innovative work on JAK2 V617F inhibitors paving the way for new treatment options. Her contributions are vital to the ongoing fight against cancer and other diseases.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile